Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2005

01-12-2005 | Clinical trial

High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer

Authors: Sophie Catherine Abrial, Frédérique Penault-Llorca, Rémi Delva, Philippe Bougnoux, Bernard Leduc, Marie-Ange Mouret-Reynier, Dominique Mery-Mignard, Jean-Pierre Bleuse, Jacques Dauplat, Hervé Curé, Philippe Chollet

Published in: Breast Cancer Research and Treatment | Issue 3/2005

Login to get access
Metadata
Title
High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer
Authors
Sophie Catherine Abrial
Frédérique Penault-Llorca
Rémi Delva
Philippe Bougnoux
Bernard Leduc
Marie-Ange Mouret-Reynier
Dominique Mery-Mignard
Jean-Pierre Bleuse
Jacques Dauplat
Hervé Curé
Philippe Chollet
Publication date
01-12-2005
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2005
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-005-9008-8

Other articles of this Issue 3/2005

Breast Cancer Research and Treatment 3/2005 Go to the issue

OriginalPaper

Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats

OriginalPaper

The time-related changes of the importance of prognostic factors in breast cancer. A sequential multivariate analysis of 1423 Japanese patients

Report

Polymorphisms of the DNA Mismatch Repair Gene HMSH2 in Breast Cancer Occurence and Progression

Report

N-cadherin Expression in Breast Cancer: Correlation with an Aggressive Histologic Variant – Invasive Micropapillary Carcinoma

Clinical trial

Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancers

Epidemiology

Cytochrome P4501A1 genetic polymorphisms and breast cancer risk in Nigerian women
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits